Monoclonal antibodies against CLDN18.2 and their Fc-engineered versions

Abstract

Optionally, the Fc region may be engineered, and the antibody may specifically bind to CLDN18.2 and A panel of monoclonal antibodies that do not specifically bind to DN18.1 is provided.

Description

[Technical Field]

[0001] This application claims priority to PCT Patent Applications Nos. PCT / CN2021 / 097239 and PCT / CN2021 / 097240, filed on May 31, 2021, and PCT Patent Applications Nos. PCT / CN2021 / 106783 and PCT / CN2021 / 106784, filed on July 16, 2021, the contents of which are incorporated herein by reference.

[0002] A panel of antibodies, optionally with engineered Fc regions, that specifically bind to CLDN18.2 but not to CLDN18.1 is provided. [Background technology]

[0003] The tight junction molecule claudin 18 splice variant 2 (claudin 18.2 (CLDN18.2)) is a member of the claudin family of tight junction proteins. CLDN18.2 is a 27.8 kDa transmembrane protein containing four transmembrane domains with two small extracellular loops.

[0004] In normal tissues, there is no detectable expression of CLDN18.2 by RT-PCR, except in the stomach, which is the only positive tissue after immunohistochemistry with a CLDN18.2-specific antibody.

[0005] CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively in short-lived differentiated gastric epithelial cells. CLDN18.2 is maintained during malignant transformation and is therefore frequently displayed on the surface of human gastric cancer cells. Furthermore, this pan-tumor antigen is ectopically activated at significant levels in esophageal, pancreatic, and lung adenocarcinomas. CLDN18.2 protein is also localized in lymph node metastases of gastric adenocarcinoma and in distant metastases, particularly in the ovaries (so-called Krukenberg tumors). Summary of the Invention

[0006] The present invention provides anti-CLDN18.2 antibodies.

[0007] The present invention provides isolated monoclonal antibodies, particularly those that are Fc-engineered, that specifically bind to human CLDN18.2, wherein the antibody (1) HVR-H1, HVR-H2, and HVR-H3 contained within VH as set forth in SEQ ID NO: 1, and HVR-L1, HVR-L2, and HVR-L3 contained within VL as set forth in SEQ ID NO: 2; (2) HVR-H1, HVR-H2, and HVR-H3 contained within VH as set forth in SEQ ID NO: 3, and HVR-L1, HVR-L2, and HVR-L3 contained within VL as set forth in SEQ ID NO: 4; (3) HVR-H1, HVR-H2, and HVR-H3 contained within VH as set forth in SEQ ID NO: 5, and HVR-L1, HVR-L2, and HVR-L3 contained within VL as set forth in SEQ ID NO: 6; or (4) VH H1, HVR-H2, and HVR-H3 contained in the VH as shown in SEQ ID NO: 7, and VL HVR-L1, HVR-L2, and HVR-L3 contained in the VL as shown in SEQ ID NO: 8, For example, as depicted in Figure 1A, 1B, 1C or 1D, optionally containing one or more mutations in the Fc region.

[0008] In one aspect, the antibody (1) HVR-H1 as represented by SEQ ID NO: 11, HVR-H2 as represented by SEQ ID NO: 12, HVR-H3 as represented by SEQ ID NO: 13, HVR-L1 as represented by SEQ ID NO: 14, HVR-L2 as represented by SEQ ID NO: 15, and HVR-L3 as represented by SEQ ID NO: 16; (2) HVR-H1 as represented by SEQ ID NO: 17, HVR-H2 as represented by SEQ ID NO: 18, HVR-H3 as represented by SEQ ID NO: 19, HVR-L1 as represented by SEQ ID NO: 20, HVR-L2 as represented by SEQ ID NO: 21, and HVR-L3 as represented by SEQ ID NO: 22; (3) HVR-H1 as represented by SEQ ID NO: 23, HVR-H2 as represented by SEQ ID NO: 24, HVR-H3 as represented by SEQ ID NO: 25, HVR-L1 as represented by SEQ ID NO: 26, HVR-L2 as represented by SEQ ID NO: 27, and HVR-L3 as represented by SEQ ID NO: 28; or (4) HVR-H1 as set forth in SEQ ID NO: 29, HVR-H2 as set forth in SEQ ID NO: 30, HVR-H3 as set forth in SEQ ID NO: 31, HVR-L1 as set forth in SEQ ID NO: 32, HVR-L2 as set forth in SEQ ID NO: 33, and HVR-L3 as set forth in SEQ ID NO: 34.

[0009] In one aspect, the antibody (1) HVR-H1 as represented by SEQ ID NO: 41, HVR-H2 as represented by SEQ ID NO: 42, HVR-H3 as represented by SEQ ID NO: 43, HVR-L1 as represented by SEQ ID NO: 44, HVR-L2 as represented by SEQ ID NO: 45, and HVR-L3 as represented by SEQ ID NO: 46; (2) HVR-H1 as represented by SEQ ID NO: 47, HVR-H2 as represented by SEQ ID NO: 48, HVR-H3 as represented by SEQ ID NO: 49, HVR-L1 as represented by SEQ ID NO: 50, HVR-L2 as represented by SEQ ID NO: 51, and HVR-L3 as represented by SEQ ID NO: 52; or (3) HVR-H1 as set forth in SEQ ID NO: 53, HVR-H2 as set forth in SEQ ID NO: 54, HVR-H3 as set forth in SEQ ID NO: 55, HVR-L1 as set forth in SEQ ID NO: 56, HVR-L2 as set forth in SEQ ID NO: 57, and HVR-L3 as set forth in SEQ ID NO: 58.

[0010] The present invention further provides isolated monoclonal antibodies, particularly those that are Fc-engineered, that specifically bind to human CLDN18.2, wherein the antibody comprises: (1) VH comprising HVR-H1 as set forth in SEQ ID NO: 11, HVR-H2 as set forth in SEQ ID NO: 12, and HVR-H3 as set forth in SEQ ID NO: 13, and VL comprising HVR-L1 as set forth in SEQ ID NO: 14, HVR-L2 as set forth in SEQ ID NO: 15, and HVR-L3 as set forth in SEQ ID NO: 16; (2) VH comprising HVR-H1 as set forth in SEQ ID NO: 17, HVR-H2 as set forth in SEQ ID NO: 18, and HVR-H3 as set forth in SEQ ID NO: 19, and VL comprising HVR-L1 as set forth in SEQ ID NO: 20, HVR-L2 as set forth in SEQ ID NO: 21, and HVR-L3 as set forth in SEQ ID NO: 22; (3) VH comprising HVR-H1 as set forth in SEQ ID NO: 23, HVR-H2 as set forth in SEQ ID NO: 24, and HVR-H3 as set forth in SEQ ID NO: 25, and VL comprising HVR-L1 as set forth in SEQ ID NO: 26, HVR-L2 as set forth in SEQ ID NO: 27, and HVR-L3 as set forth in SEQ ID NO: 28; or (4) A VH comprising HVR-H1 as represented by SEQ ID NO: 29, HVR-H2 as represented by SEQ ID NO: 30, and HVR-H3 as represented by SEQ ID NO: 31, and HVR-L1 as represented by SEQ ID NO: 32, HVR-L2 as represented by SEQ ID NO: 33 -L2, and a VL comprising HVR-L3 as set forth in SEQ ID NO: 34, Optionally, it may contain one or more mutations in the Fc region.

[0011] The present invention further provides isolated monoclonal antibodies, particularly those that are Fc-engineered, that specifically bind to human CLDN18.2, wherein the antibody comprises: (1) A VH comprising HVR-H1 as set forth in SEQ ID NO: 41, HVR-H2 as set forth in SEQ ID NO: 42, and HVR-H3 as set forth in SEQ ID NO: 43, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 44, HVR-L2 as set forth in SEQ ID NO: 45, and HVR-L3 as set forth in SEQ ID NO: 46; (2) VH comprising HVR-H1 as set forth in SEQ ID NO: 47, HVR-H2 as set forth in SEQ ID NO: 48, and HVR-H3 as set forth in SEQ ID NO: 49, and VL comprising HVR-L1 as set forth in SEQ ID NO: 50, HVR-L2 as set forth in SEQ ID NO: 51, and HVR-L3 as set forth in SEQ ID NO: 52; or (3) A VH comprising HVR-H1 as set forth in SEQ ID NO: 53, HVR-H2 as set forth in SEQ ID NO: 54, and HVR-H3 as set forth in SEQ ID NO: 55, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 56, HVR-L2 as set forth in SEQ ID NO: 57, and HVR-L3 as set forth in SEQ ID NO: 58; Optionally, it may contain one or more mutations in the Fc region.

[0012] The present invention further provides isolated monoclonal antibodies, particularly those that are Fc engineered, that specifically bind to human CLDN18.2, wherein the antibody (1) VH as set forth in SEQ ID NO: 1 and VL as set forth in SEQ ID NO: 2; (2) a VH as set forth in SEQ ID NO: 3 and a VL as set forth in SEQ ID NO: 4; (3) a VH as set forth in SEQ ID NO: 5 and a VL as set forth in SEQ ID NO: 6; or (4) A VH as set forth in SEQ ID NO: 7 and a VL as set forth in SEQ ID NO: 8, optionally, comprising one or more mutations in the Fc region; Optionally, the first two amino acid residues at the N-terminus of VH are absent.

[0013] In one embodiment, the one or more mutations in the Fc region are one or more mutations that modify (e.g., increase or decrease) binding to an Fc receptor and / or effector function, such as ADCC and / or CDC. In one embodiment, the one or more mutations in the Fc region are one or more substitutions selected from the group consisting of L235V, F243L, R292P, Y300L, and P396L. In one embodiment, the one or more mutations in the Fc region are L235V, F243L, R292P, Y300L, and P396L.

[0014] The present invention further provides isolated monoclonal antibodies, particularly Fc-engineered, that specifically bind to human CLDN18.2, wherein the antibody comprises: i) competes for binding to human CLDN18.2 with an anti-CLDN18.2 antibody comprising: (1) a VH as set forth in SEQ ID NO: 1 and a VL as set forth in SEQ ID NO: 2; (2) a VH as set forth in SEQ ID NO: 3 and a VL as set forth in SEQ ID NO: 4; (3) a VH as set forth in SEQ ID NO: 5 and a VL as set forth in SEQ ID NO: 6; or (4) a VH as set forth in SEQ ID NO: 7 and a VL as set forth in SEQ ID NO: 8; and / or ii) (1) a VH as set forth in SEQ ID NO: 1 and a VL as set forth in SEQ ID NO: 2; (2) a VH as set forth in SEQ ID NO: 3 and a VL as set forth in SEQ ID NO: 4; (3) a VH as set forth in SEQ ID NO: 5 and a VL as set forth in SEQ ID NO: 6; or (4) an anti-CLDN18.2 antibody comprising a VH as set forth in SEQ ID NO: 7 and a VL as set forth in SEQ ID NO: 8, which binds to the same epitope of human CLDN18.2 as an anti-CLDN18.2 antibody comprising a VH as set forth in SEQ ID NO: 7 and a VL as set forth in SEQ ID NO: 8; and / or iii) ADCC of PBMCs on cells expressing human CLDN18.2 (e.g., 293T cells, CHO cells, CT26 cells, KATOIII cells, or NCI-N87 cells) was measured by, for example, LDH or FACS, at 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, ...10 nM, 10 nM, 10 nM, 10 nM, 10 nM, with an EC50 value of, near, or less than 0.2 nM, 0.1 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, 0.05 nM, 0.04 nM, 0.03 nM, 0.02 nM, 0.01 nM, 0.009 nM, 0.008 nM, 0.007 nM, 0.006 nM, 0.005 nM, 0.004 nM, 0.003 nM, 0.002 nM, or 0.001 nM; and / or iv) does not mediate ADCC of PBMCs on cells expressing human CLDN18.1 (e.g., 293T cells, CHO cells, CT26 cells, KATOIII cells, or NCI-N87 cells); and / or v) CDC on cells expressing human CLDN18.2 (e.g., 293T cells, CHO cells, CT26 cells, KATOIII cells, or NCI-N87 cells) at 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.09 nM, 0.08 nM, 0.07 nM, 0.06 nM, as determined by, for example, LDH or FACS. with an EC50 value of, near, or less than 0.05 nM, 0.04 nM, 0.03 nM, 0.02 nM, 0.01 nM, 0.009 nM, 0.008 nM, 0.007 nM, 0.006 nM, 0.005 nM, 0.004 nM, 0.003 nM, 0.002 nM, or 0.001 nM; and / or vi) does not mediate CDC on cells expressing human CLDN18.1 (e.g., 293T cells, CHO cells, CT26 cells, KATOIII cells, or NCI-N87 cells); and / or vii) binds to cells expressing human CLDN18.2 on the cell surface (e.g., 293T cells or CHO cells) with a Kd of, near, or less than, e.g., 50 pM, 45 pM, 40 pM, 38.6 pM, 35 pM, 30 pM, 25 pM, 20 pM, 15 pM, 13.1 pM, 10 pM, 9.5 pM, 9 pM, or 5 pM; and / or viii) does not bind to cells expressing human CLDN18.1 on the cell surface (e.g., 293T cells or CHO cells); and / or ix) specifically binds to human CLDN18.2 with a Kd value of, near, or less than, e.g., 10 nM, 9.5 nM, 9 nM, 8.5 nM, 8 nM, 7.5 nM, 7 nM, 6.5 nM, 6.4 nM, 6 nM, 5.5 nM, 5 nM, 4.5 nM, 4 nM, 3.8 nM, 3.5 nM, 3 nM, 2.5 nM, 2 nM, 1.7 nM, 1.5 nM, or 1 nM; and / or x) It does not specifically bind to human CLDN CLDN18.1.

[0015] In one embodiment, the anti-CLDN18.2 monoclonal antibody of the invention is a murine, chimeric, or humanized antibody.

[0016] In one embodiment, the anti-CLDN18.2 monoclonal antibody of the invention is an antigen-binding antibody fragment, optionally a Fab fragment, a Fab' fragment, or a F(ab')2 fragment. fragments, scFv fragments, and diabodies. That's fine.

[0017] In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention is a full-length antibody. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention comprises a heavy chain constant region of human IgG (particularly IgG1), optionally as set forth in SEQ ID NO: 9. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention comprises a mutated human IgG (particularly IgG1) heavy chain constant region, optionally as set forth in SEQ ID NO: 40. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention comprises a human kappa light chain constant region, optionally as set forth in SEQ ID NO: 10. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention is a chimeric antibody, e.g., a murine / human chimeric antibody. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention is Fc-engineered.

[0018] In one embodiment, a monoclonal antibody (mAb) or Fab fragment of the invention has a crossover format (x-mAb or x-Fab), in which either the variable domains or the (first) constant domains of the light and heavy chain variable domains are exchanged.

[0019] The present invention provides isolated nucleic acids encoding the monoclonal antibodies of the invention. The present invention provides vectors, e.g., cloning vectors or expression vectors, comprising the nucleic acids of the invention. The present invention provides host cells comprising the nucleic acids of the invention or the vectors of the invention. The present invention provides methods for producing the monoclonal antibodies of the invention, comprising culturing the host cells to produce the antibody. In one aspect, the method further comprises recovering the antibody from the host cells or cell culture medium.

[0020] The present invention provides compositions comprising the monoclonal antibodies of the present invention. The present invention provides pharmaceutical formulations comprising the monoclonal antibodies of the present invention and a pharmaceutically acceptable carrier.

[0021] The present invention provides a monoclonal antibody of the present invention for use as a medicament. The present invention provides a monoclonal antibody of the present invention for use in treating cancer. The present invention provides use of a monoclonal antibody of the present invention for the manufacture of a medicament. In one aspect, the medicament is used for treating cancer. The present invention provides a method of treating an individual with cancer, comprising administering to the individual a therapeutically effective amount of a monoclonal antibody of the present invention. [Brief explanation of the drawings]

[0022] [Figure 1A] Figure 1A shows an alignment of the amino acid sequences of the VH and VL of antibodies of the invention, with HVRs according to Kabat highlighted by shading. [Figure 1B] Figure 1B shows an alignment of the amino acid sequences of the VH and VL of antibodies of the invention, with HVRs according to IMGT highlighted by shading. [Figure 1C] Figure 1C shows an alignment of the amino acid sequences of the VH and VL of antibodies of the invention, with HVRs according to Chothia highlighted by shading. [Figure 1D] Figure ID shows an alignment of the amino acid sequences of VH and VL of antibodies of the present invention, with HVRs that follow contacts highlighted by shading. [Figure 2] FIG. 2 shows the binding of the antibody of the present invention to CLDN18.2-expressing cells. [Figure 3] FIG. 3 shows the binding of the antibody of the present invention to CLDN18.1-expressing cells. [Figure 4] FIG. 4 shows ADCC on CLDN18.2-expressing cells mediated by antibodies of the invention. [Figure 5] FIG. 5 shows the binding curves of antibodies of the present invention to huCLDN18.2. [Figure 6] FIG. 6 shows the binding curve of the antibody of the present invention to cells expressing huCLDN18.2. [Figure 7] FIG. 7 shows the results of ADCC assay of the antibody of the present invention. [Figure 8] FIG. 8 shows the results of a cell binding assay of the antibody of the present invention. [Figure 9] FIG. 9 shows the results of a CDC assay of the antibody of the present invention. [Figure 10] FIG. 10 shows the results of ADCC assay of the antibody of the present invention. [Figure 11] FIG. 11 shows the CDC effect mediated by antibodies of the invention on CLDN18.2-expressing CT26 cells as determined by LDH assay. [Figure 12] FIG. 12 shows the CDC effect mediated by the antibodies of the present invention on CLDN18.2-expressing KATOIII cells as determined by LDH assay. [Figure 13] FIG. 13 shows the ADCC effect mediated by the antibodies of the present invention against CLDN18.2-expressing KATOIII cells, as determined by LDH assay. [Figure 14] FIG. 14 shows the ADCC effect mediated by the antibodies of the present invention against NCI-N87 expressing CLDN18.2, as determined by LDH assay. DETAILED DESCRIPTION OF THE INVENTION

[0023] I. Definition The term "antibody" as used herein is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

[0024] "Antibody fragment" refers to a molecule other than an intact antibody that contains the portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibodies formed from antibody fragments.

[0025] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0026] The "class" of an antibody refers to the type of constant domain or constant region carried by its heavy chain. There are five major antibody classes: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. Light chains can be assigned to one of two clearly distinct types, called kappa ("κ") and lambda ("λ"), based on the amino acid sequence of their constant domain.

[0027] "Effector function" refers to a biological activity attributable to the Fc region of an antibody, which varies depending on the antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

[0028] As used herein, the terms "engineer, engineered, manipulating" refer to any manipulation of the peptide backbone or the structure of a naturally occurring or recombinant polypeptide or polypeptides thereof. It is believed to include post-translational modifications of the fragments. Engineering includes modifications of the amino acid sequence, glycosylation patterns, or side groups of individual amino acids, as well as combinations of these techniques.

[0029] The term "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain containing at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. In one embodiment, the anti-CLDN18.2 antibody described herein is of the IgG1 isotype and comprises the heavy chain constant region of SEQ ID NO: 9 or SEQ ID NO: 40. In one embodiment, it further comprises a C-terminal lysine (Lys447). Unless otherwise specified herein, the numbering of amino acid residues within the Fc region or constant region is in accordance with Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, It follows the EU numbering system, also known as the EU index, as described in 1991.

[0030] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, the HVR and FR sequences generally appear in VH (or VL) in the following order: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0031] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a native antibody structure or having a heavy chain that includes an Fc region as defined herein.

[0032] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and its progeny regardless of the number of transfers. The progeny may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0033] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues derived from non-human HVRs and human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) in the variable domain correspond to HVRs of a non-human antibody, and all or substantially all of the FRs correspond to FRs of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0034] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is hypervariable in sequence ("complementarity determining region" or "CDR") and / or forms structurally defined loops ("hypervariable loops") and / or contains antigen-contacting residues ("antigen contacts"). Generally, antibodies contain six HVRs: three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). Exemplary HVRs herein include: (a) Hypervariable loops present at amino acid residues 26–32 (L1), 50–52 (L2), 91–96 (L3), 26–32 (H1), 53–55 (H2), and 96–101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901–917 (1987)); (b) CDRs present at amino acid residues 24–34 (L1), 50–56 (L2), 89–97 (L3), 31–35b (H1), 50–65 (H2), and 95–102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)); (c) antigen contacts present at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); and (d) combinations of (a), (b), and / or (c) including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3); HVR residues can be identified on websites such as https: / / www.novopro.cn / tools / cdr.html.

[0035] Unless otherwise specified, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.

[0036] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies contained in the population are identical and / or bind to the same epitope, except for possible variant antibodies containing, for example, naturally occurring mutations or arising during purification of the monoclonal antibody preparation (such variants are generally present in small amounts). In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies to be used in accordance with the present invention may be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci; such methods and other exemplary methods for producing monoclonal antibodies are described herein.

[0037] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains (VH and VL, respectively) of native antibodies generally have a similar structure, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR). See, for example, Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a specific antigen may be isolated by screening a library of complementary VL or VH domains, respectively, using the VH or VL domain of an antibody that binds to the antigen. See, for example, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-6 28(1991).

[0038] The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures and vectors that integrate into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0039] II. Exemplary Antibodies The present invention provides isolated monoclonal antibodies, particularly those that are Fc-engineered, that specifically bind to human CLDN18.2, wherein the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 11, HVR-H2 as set forth in SEQ ID NO: 12, and HVR-H3 as set forth in SEQ ID NO: 13, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 14, HVR-L2 as set forth in SEQ ID NO: 15, and HVR-L3 as set forth in SEQ ID NO: 16. In one embodiment, the antibody comprises a VH as set forth in SEQ ID NO: 1 and a VL as set forth in SEQ ID NO: 2. Optionally, the first two amino acid residues at the N-terminus of the VH are not present.

[0040] The present invention provides an isolated monoclonal antibody, particularly one that is Fc-engineered, that specifically binds to human CLDN18.2, wherein the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 17, HVR-H2 as set forth in SEQ ID NO: 18, and HVR-H3 as set forth in SEQ ID NO: 19, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 20, HVR-L2 as set forth in SEQ ID NO: 21, and HVR-L3 as set forth in SEQ ID NO: 22. The present invention provides an isolated monoclonal antibody, particularly one that is Fc-engineered, that specifically binds to human CLDN18.2, wherein the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 41, HVR-H2 as set forth in SEQ ID NO: 42, and HVR-H3 as set forth in SEQ ID NO: 43, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 44, HVR-L2 as set forth in SEQ ID NO: 45, and HVR-L3 as set forth in SEQ ID NO: 46. The present invention provides an isolated monoclonal antibody, particularly one that is Fc-engineered, that specifically binds to human CLDN18.2, wherein the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 47, HVR-H2 as set forth in SEQ ID NO: 48, and HVR-H3 as set forth in SEQ ID NO: 49, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 50, HVR-L2 as set forth in SEQ ID NO: 51, and HVR-L3 as set forth in SEQ ID NO: 52. The present invention provides an isolated monoclonal antibody, particularly one that is Fc-engineered, that specifically binds to human CLDN18.2, wherein the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 53, HVR-H2 as set forth in SEQ ID NO: 54, and HVR-H3 as set forth in SEQ ID NO: 55, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 56, HVR-L2 as set forth in SEQ ID NO: 57, and HVR-L3 as set forth in SEQ ID NO: 58. In one embodiment, the antibody comprises a VH as set forth in SEQ ID NO: 3 and a VL as set forth in SEQ ID NO: 4. Optionally, the first two amino acid residues at the N-terminus of the VH are absent.

[0041] The present invention provides isolated monoclonal antibodies, particularly those that are Fc-engineered, that specifically bind to human CLDN18.2, wherein the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 23, HVR-H2 as set forth in SEQ ID NO: 24, and HVR-H3 as set forth in SEQ ID NO: 25, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 26, HVR-L2 as set forth in SEQ ID NO: 27, and HVR-L3 as set forth in SEQ ID NO: 28. In one embodiment, the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 23, HVR-H2 as set forth in SEQ ID NO: 24, and HVR-H3 as set forth in SEQ ID NO: 25. 5 and a VL as set forth in SEQ ID NO: 6. Optionally, the first two amino acid residues at the N-terminus of the VH are absent.

[0042] The present invention provides isolated monoclonal antibodies, particularly those that are Fc-engineered, that specifically bind to human CLDN18.2, wherein the antibody comprises a VH comprising HVR-H1 as set forth in SEQ ID NO: 29, HVR-H2 as set forth in SEQ ID NO: 30, and HVR-H3 as set forth in SEQ ID NO: 31, and a VL comprising HVR-L1 as set forth in SEQ ID NO: 32, HVR-L2 as set forth in SEQ ID NO: 33, and HVR-L3 as set forth in SEQ ID NO: 34. In one embodiment, the antibody comprises a VH as set forth in SEQ ID NO: 7 and a VL as set forth in SEQ ID NO: 8. Optionally, the first two amino acid residues at the N-terminus of the VH are not present.

[0043] In one embodiment, the one or more mutations in the Fc region are one or more mutations that modify (e.g., increase or decrease) binding to an Fc receptor and / or effector function, such as ADCC and / or CDC. In one embodiment, the one or more mutations in the Fc region are one or more substitutions selected from the group consisting of L235V, F243L, R292P, Y300L, and P396L. In one embodiment, the one or more mutations in the Fc region are L235V, F243L, R292P, Y300L, and P396L.

[0044] In one embodiment, the anti-CLDN18.2 monoclonal antibody of the invention is a murine, chimeric, or humanized antibody.

[0045] In one embodiment, the anti-CLDN18.2 monoclonal antibody of the invention is an antigen-binding antibody fragment, optionally a Fab fragment, a Fab' fragment, or a F(ab')2 fragment. The antibody may be selected from the group consisting of an antibody fragment, an scFv fragment, and a diabody.

[0046] In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention is a full-length antibody. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention comprises a heavy chain constant region of human IgG (particularly IgG1), optionally as set forth in SEQ ID NO: 9. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention comprises a mutated human IgG (particularly IgG1) heavy chain constant region, optionally as set forth in SEQ ID NO: 40. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention comprises a human kappa light chain constant region, optionally as set forth in SEQ ID NO: 10. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention is a chimeric antibody, e.g., a murine / human chimeric antibody. In one embodiment, the anti-CLDN18.2 monoclonal antibody of the present invention is Fc-engineered.

[0047] In one embodiment, a monoclonal antibody (mAb) or Fab fragment of the invention has a crossover format (x-mAb or x-Fab), in which either the variable domains or the (first) constant domains of the light and heavy chain variable domains are exchanged.

[0048] III. Recombinant Methods and Compositions Antibodies can be produced using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567. These methods provide one or more isolated nucleic acids encoding the antibody.

[0049] In the case of a native antibody or native antibody fragment, two nucleic acids are required: one for the light chain or fragment thereof, and one for the heavy chain or fragment thereof. Such nucleic acids encode an amino acid sequence comprising the VL of the antibody and / or an amino acid sequence comprising the VH of the antibody (e.g., the light and / or heavy chains of the antibody). These nucleic acids are the same They can be on the expression vector or on different expression vectors.

[0050] In one aspect, an isolated nucleic acid encoding an antibody for use in the methods described herein is provided.

[0051] In a further aspect, one or more vectors (eg, expression vectors) comprising such nucleic acid(s) are provided.

[0052] In a further aspect, a host cell comprising such nucleic acid(s) is provided.

[0053] In one such embodiment, the host cell comprises (e.g., is transformed with) the following vector: (1) A vector containing a nucleic acid encoding an amino acid sequence containing an antibody VL and an amino acid sequence containing an antibody VH, or (2) A first vector containing a nucleic acid encoding an amino acid sequence comprising the VL of the antibody, and a second vector containing a nucleic acid encoding an amino acid sequence comprising the VH of the antibody.

[0054] In one embodiment, the host cell is a eukaryotic cell, such as a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., a Y0, NS0, or Sp20 cell). In one embodiment, a method of producing an antibody is provided, comprising culturing a host cell containing an antibody-encoding nucleic acid as provided above under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell or host cell culture medium.

[0055] For recombinant production of an antibody, nucleic acid encoding the antibody is isolated and inserted into one or more vectors for further cloning and / or expression in host cells, e.g., as described above. Such nucleic acid can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the antibody heavy and light chains).

[0056] Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, 2001, describing the expression of antibodies in E. coli.) Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254. After expression, the antibody is isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0057] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungal or yeast strains whose glycosylation pathways have been "humanized," resulting in the production of antibodies with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

[0058] Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Several baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

[0059] Plant cell cultures can be used as hosts. See, e.g., U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (PLANTIBODIES FOR ANTIBODY PRODUCTION IN TRANSGENIC PLANTS). TM See (describe the technology).

[0060] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to grow in suspension can be useful. Other examples of useful mammalian host cell lines include the SV40 (COS-7) transformed monkey kidney CV1 line, the human embryonic kidney line (Graham et al., J. Gen Virol. 36:59 (1977); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); human lung cells (W138); human hepatocytes (HepG2); mouse mammary tumor (MMT060562); TRI cells described, for example, in Mather JP et al., Annals NY Acad. Sci. 383:(1982) 44-68; MRC5 cells; and FS4 cells. Other useful mammalian host cell lines are DHFR-CHO cells (Urlaub G. et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980) and myeloma cell lines such as Y0, NS0, and Sp2 / 0. For a review of specific mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, A.M. Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2004).

[0061] IV. Assay The antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity by various assays known in the art.

[0062] Binding and other assays In one embodiment, the antibodies of the invention are tested for their antigen binding activity, for example, by known methods, such as ELISA, Western blot, and the like.

[0063] In another embodiment, a competition assay can be used to identify antibodies that compete with CLDN18.2 for binding to CLDN18.2. In certain embodiments, such competing antibodies bind to the same epitope (e.g., a linear or conformational epitope) bound by CLDN18.2 (see, e.g., Example 1 and Table 4). Detailed exemplary methods for mapping the epitope to which an antibody binds can be found in Methods in Morris (1996) "Epitope Mapping Protocols," in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).

[0064] In a typical competitive assay, immobilized CLDN18.2 is subjected to a first labeled antibody (e.g., one or more antibodies disclosed herein) that binds to CLDN18.2, and a second labeled antibody (e.g., one or more antibodies disclosed herein) that binds to CLDN18.2. The test sample is incubated in a solution containing a second, unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to CLDN18.2. The second antibody may be present in the hybridoma supernatant. As a control, immobilized CLDN18.2 is incubated in a solution containing the labeled first antibody, but not the unlabeled second antibody. After incubation under conditions that allow binding of the first antibody to CLDN18.2, excess unbound antibody is removed, and the amount of label bound to the immobilized CLDN18.2 is measured. If the amount of label bound to the immobilized CLDN18.2 is substantially reduced in the test sample compared to the control sample, this indicates that the second antibody competes with the first antibody for binding to CLDN18.2. Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, See NY).

[0065] Activity assay In one embodiment, assays are provided to identify those anti-CLDN18.2 antibodies that have biological activity. Biological activity can include, for example, ADCC of the anti-CLDN18.2 antibody by PBMCs against target cells that express CLDN18.2. Antibodies that have such biological activity in vivo and / or in vitro are also provided. [Example]

[0066] Initial screening results identified four positive hybridoma cell lines derived from immunized mice that specifically bound to CLDN18.2-expressing cells but not to CLDN18.1-expressing cells.

[0067] Example 1: Cloning of four CLDN18.2-specific monoclonal antibodies (mAbs) from mouse hybridoma cells This example demonstrates that antibody H-chain and L-chain genes were cloned from mouse hybridoma cells to obtain variable region sequences specific to CLDN18.2, and a chimeric antibody was produced.

[0068] RNA was isolated and purified from hybridoma cells using a Quick-RNA™ Microprep Kit (ZYMO Research, Cat. # R1050) according to conventional procedures. First-strand cDNA was synthesized and RACE was performed using the SMARTer® RACE 5' / 3' kit (Takara Bio USA, Inc., Cat. # 634858) with the IgG1 3' constant primer (SEQ ID NO: 35), IgG2a 3' constant primer (SEQ ID NO: 36), and Kappa 3' constant primer (SEQ ID NO: 37). The RACE DNA product was subjected to gel extraction using a NuceloSpin Gel and PCR Clean-Up kit (Takara, Cat. # 740986.20). The in-fusion reaction mixture of the linearized pRACE vector and the gel-purified pRACE product was transformed into Stellar competent cells (Clontech, Cat. # 636766). Plasmid DNA was isolated from the transformants using a QIAprep Spin Miniprep Kit (Qiagen, Cat. # 27104) and subjected to Sanger sequencing (GENEWIZ) using M13 sequencing primers. The final gene sequences of four pairs of heavy and light chains were obtained (data not shown), and these were identified as the following CLDN18.2 mAbs (mAb1, mAb2, mAb3, mAb4).

[0069] Example 2: Construction of chimeric antibodies in which mouse constant regions are replaced with human constant regions In this example, the constant regions of four molecularly cloned mouse mAbs were cloned into human IgG

[0043] Figure 1 is an example showing the construction of a chimeric antibody by replacing one heavy chain with another from a kappa light chain.

[0070] Plasmid pFUSE-CHIg-hG1 (InvivoGen, Cat. # pfuse-hchg1) (SEQ ID NO: 9), which contains the constant region of the human IgG1 heavy chain, and plasmid pFUSE2-CLIg-hk (InvivoGen, Cat. # pfuse2-hclk), which contains the constant region of the human kappa light chain (SEQ ID NO: 10), were digested with Hind III and Nhe I (for IgG1) or BsiW I (for kappa) (all from the NEB lab). The linearized plasmids were gel purified using NucleoSpin Gel and a PCR Clean-up kit (Takara, Cat. # 740986.20). The coding sequences for the mouse heavy and light chain variable regions of mAb1, mAb2, mAb3, and mAb4 were PCR amplified from the plasmids obtained in Example 1 with specific primers using HiFi HotStart (Kapa (Roche), KK2602) (data not shown) and purified by gel purification using a NucleoSpin Gel and PCR Clean-up kit (Takara, Cat.# 740986.20). The linearized vector and insert were ligated using the Gibson Assembly® HiFi 1 Step Kit (SGI (VWR), Cat.# GA1100-50). The assembly reaction mixture was transformed into Stellar competent cells (Clontech, Cat.# 636766). Plasmid DNA was purified using the QIAprep Spin Miniprep Kit. (Qiagen, Cat. # 27104) and subjected to Sanger sequencing (GENEWIZ). Four chimeric antibodies containing one of the four mouse mAbs prepared in Example 1 were constructed. The new chimeric antibodies were designated YL-G1-19-01, YL-G1-19-02, YL-G1-19-03, and YL-G1-19-04.

[0071] Example 3: Confirmation of the specificity of four chimeric monoclonal antibodies by surface staining This example tests the binding specificity of four chimeric monoclonal antibodies to CLDN18.2 in comparison with a reference mAb (IMAB362, Ganymed).

[0072] 2 x 10 in FACS buffer 6 CLDN18.2- and CLDN18.1-expressing 293T cells (50 μL) at a density of cells / ml were mixed with 50 μL of a dilution series of chimeric antibodies, reference antibodies, or IgG negative control (60.00, 20.00, 6.67, 2.22, 0.74, 0.25, and 0.08 μg / mL in FACS buffer) in a 96-well V-bottom plate and incubated on ice for 30 minutes. After washing with 200 μL / well of FACS buffer, the cells were resuspended in 30 μL / well of secondary antibody Alexa Fluor® 647 AffiniPure Goat Anti-Human IgG, Fcγ fragment specific (Jackson, Cat. #109-605-098) and incubated on ice for 20 minutes. After washing three times with 200 μL / well FACS buffer, the cells were resuspended in 150 μL / well FACS buffer and subjected to FACS using a BD LSR II flow cytometer (HTS). Data were analyzed using geometric means, and plots were generated using Prism GraphPad. Flow cytometry analysis demonstrated that the four chimeric antibodies had high specific binding to CLDN18.2-expressing cells compared to the reference mAb (see Figure 2). No binding to CLDN18.1-expressing cells was observed (see Figure 3), suggesting the high specificity of the four chimeric antibodies.

[0073] Example 4: Functional confirmation of four chimeric antibodies by ADCC assay This example tests the ADCC-mediated cytotoxicity of these four chimeric antibodies in comparison with a reference mAb (IMAB362, Ganymed).

[0074] CLDN18.2- and CLDN18.1-expressing 293T cells were labeled with CFSE using eBioscience™ CFSE (Thermo, Cat. #65-0850-84). 4 x 10 cells were cultured in 50 μL of Lympholyte® Cell Separation Media (Cedarlane, Cat. # CL5110). 5 CFSE-labeled cells at a density of 5 × 10 cells / ml were mixed with 100 μL of a dilution series (20.00, 6.67, 2.22, 0.74, 0.25, 0.08, and 0.03 μg / mL in medium) of chimeric antibodies, reference antibodies, or IgG negative control in a 96-well V-bottom plate and incubated in the dark at room temperature for 15 minutes. 6 PBMCs (50 μL) were added at a density of 100 cells / ml, and the plate was incubated at 37°C in the dark for 2 hours. Cells were washed twice with PBS, and 100 μL of a working solution of eBioscience™ Fixable Viability Dye eFluor™ 660 (Thermo, Cat. # 65-0864) was added per well. The plate was incubated on ice in the dark for 30 minutes. After washing with PBS, cells were resuspended in 75 μL / well of PBS and 25 μL / well of 4% paraformaldehyde and subjected to FACS analysis using a BD LSR II Flow Cytometer (HTS). Data were analyzed using the injury rate (CFSE-positive population vs. CFSE / FVD-AF660 double-positive population), and plots were generated using Prism GraphPad. FACS-based ADCC activity analysis demonstrated that the four chimeric antibodies were able to mediate ADCC activity against CLDN18.2-expressing cells (see Figure 4).

[0075] Example 5: Characterization of Fc-engineered chimeric antibodies Additionally, four Fc-engineered chimeric antibodies were constructed. Compared to the first-generation initial chimeric antibodies YL-G1-19-01, YL-G1-19-02, YL-G1-19-03, and YL-G1-19-04, the second-generation Fc-engineered chimeric antibodies YL-G2-A, YL-G2-B, YL-G2-C, and YL-G2-D (compared to YL-G1-19-04, YL-G2-D lacks the first two N-terminal amino acid residues of the VH domain) contain five Fc region substitutions according to EU numbering: L235V, F243L, R292P, Y300L, and P396L. The mutant constant region (including CH1, hinge, CH2, and CH3) of the human IgG1 heavy chain is set forth in SEQ ID NO: 40.

[0076] This example describes the characterization of these Fc-engineered chimeric antibodies.

[0077] 5.1: Antigen-antibody binding interactions. This example illustrates the characterization of the antigen-antibody binding interactions of YL-G2-B, YL-G2-C, and YL-G2-D.

[0078] The in vitro bioactivity of YL-G2-B, YL-G2-C, and YL-G2-D was analyzed by monitoring their binding to recombinant huCLDN18.2-Fc and huCLDN18.2-overexpressing CHO cells using a KinExA 4000 system (KinExA, US).

[0079] To measure affinity using the KinExA method, serial dilutions of binding partner B (known as the titrant) are performed in a background of binding partner A (known as the constant binding partner, CBP). That is, CBP is held at a constant concentration, while the titrant is varied in concentration. Once these solutions reach equilibrium, the KinExA 4000 instrument can directly measure the amount of unbound, or free, binding partner CBP remaining in solution. Using Sapidyne software, the percent release of CBP can be plotted against the total titrant concentration to generate a binding curve and determine affinity.

[0080] Kd was first measured using antibodies purchased from Sino Biological Co., Ltd. and recombinant human CLDN18.2 (P / N: 20047-H02H). For equilibrium experiments, the titer (huCLDN18.2) was serially diluted 5-fold in a background of CBP. Two equilibrium experiments were performed: one with a high concentration of 10 nM CBP (20 nM binding sites) plus a 5-fold serial dilution of 150 nM titer; the other with a low concentration of 100 pM CBP (200 pM binding sites) plus a 5-fold serial dilution of 150 nM titer. Data were collected on a KinExA 4000 and analyzed using Sapidyne Instruments n-Curve Analysis Software version 4.4.26. Binding curves are shown in Figure 5.

[0081] The KinExA 4000 instrument was also used to measure the binding affinity of the antibody to the surface protein of intact cells, i.e., CHO cells overexpressing huCLDN18.2. The antibody concentration was kept constant (CBP) while the concentration of whole cells containing the surface protein was varied (titration). The concentration of whole cells containing the surface protein was diluted three-fold. The titrated cells were incubated with the constant binding partner (CBP). Upon reaching equilibrium, the samples were centrifuged, the supernatant was collected, and free CBP was detected with a fluorescently labeled anti-CBP molecule. The binding curve is shown in Figure 6.

[0082] To determine the Kd more accurately, two equilibrium curves were constructed and analyzed. One was at low concentrations of CBP, 100 pM (200 pM binding site) and 10 6 One curve was a 3-fold dilution of cells / mL, and the other was a high concentration of CBP at 10 nM (20 nM binding site) and 10 6 The curves are for 3-fold dilutions in cells / mL. The KinExA 4000 measured the amount of unbound CBP in solution. Analysis was performed using Sapidyne Instruments n-Curve Analysis Software version 4.4.26. The equilibrium dissociation constants, Kd, ​​are summarized in Table 1.

[0083] [Table 1]

[0084] 5.2: Cell binding assay In this example, cell binding assays of YL-G2-B, YL-G2-C, and YL-G2-D are described.

[0085] To assess antibody binding, CHO cells expressing huCLDN18.2 were used. For each sample, 5 × 10 cells were added per 100 μl to one well of a 96-well plate. 5 Cells were seeded at 100 μl each. Serially diluted antibodies were then added to the cells, starting at 40 μg / ml and diluted 5-fold. Thus, the final concentration of each antibody was 20 μg / ml. Starting with 1, 5-fold serial dilutions were performed. After 1 hour, cells were washed twice and 100 μl of GAH-FITC (1:200 dilution) was added to each well. After 30 minutes, cells were washed twice and resuspended in 120 μl of FACS buffer. These cells were analyzed by flow cytometry.

[0086] Using unstained cells as a reference, we set the gating for the entire target cell population and established the FITC-negative population, which allowed us to establish the FITC-positive cell gate for each cell line. Furthermore, to secondary verify the FITC-positive results, we calculated the mean fluorescence intensity (MFI) of the entire cell population. The ratio of the number of gated positive cells to the total number of live cells was used as the percentage of positive cells. The results are shown in Figure 7.

[0087] 5.3: Complement-dependent cytotoxicity (CDC) assay In this example, a complement-dependent cytotoxicity (CDC) assay of YL-G2-B, YL-G2-C, and YL-G2-D is described.

[0088] Target cells (i.e., CHO cells expressing huCLDN18.2) were washed once with DPBS and then cultured at 2 × 10 4 Cells were seeded into a U-bottom plate at 100 μL / well. Antibodies were serially diluted 1:2 and incubated with the cells at 50 μL / well for 15 minutes at room temperature. Next, 50 μL / well of 20% pooled serum was added to all wells, including the spontaneous and maximum release wells. The plate was incubated in a 37°C incubator for 3.5 hours. 45 minutes before the end of the incubation, the plate was centrifuged at 1200 rpm for 5 minutes, and 20 μL of lysis buffer (CyQUANT™ LDH Cytotoxicity Assay Kit, Cat.# C20300 and C20301) was added only to the maximum release control wells containing target cells. 50 μL of the supernatant was transferred to a black-walled 96-well plate and 50 μL / well of Reaction A buffer (CyQUANT™ LDH Cytotoxicity Assay Kit, Cat.# C20300 and C20301) was added to all wells, as well as to the maximum release and spontaneous release wells. The plate was incubated in the dark for 30 minutes. After the incubation, 50 μL of Stop solution (CyQUANT™ LDH Cytotoxicity Assay Kit, Cat.# C20300 and C20301) was added to all wells and gently mixed by tapping. OD was measured at 490 nM and 680 nM. Activity is expressed as % cytotoxicity. % cytotoxicity = (experimental value - target cell spontaneous release, uncorrected for volume) / (maximum target cell release - target cell spontaneous release, corrected for volume) * 100. The results are shown in Figure 8.

[0089] 5.4: Internalization assay. In this example, internalization assays of YL-G2-B, YL-G2-C, and YL-G2-D are described.

[0090] 5 x 10 cells in DMEM medium 5 CHO cells expressing huCLDN18.2 at 100 μL / ml were prepared. 100 μL of cells were seeded into each well of a U-bottom 96-well plate. Test and control antibodies were diluted to 40 μg / ml, and each antibody was serially diluted 1:4 in culture medium. 50 μl of each diluted antibody was added to the cells at 50 μl / well. The plate was incubated at 37°C for 30 minutes. Next, 40 μg / ml of PEP-ZAP (a small Fc-binding peptide fused to a cytotoxic peptide, developed by AB Studio Inc.; see WO 2020 / 018732 A1) was added to each well at 50 μl / well, resulting in a final PEP-ZAP concentration of 10 μg / ml. The plate was incubated at 37°C for 72 hours. Finally, the cells were spun, and 100 μl of the supernatant was removed for LDH measurement. The results are shown in Figure 9.

[0091] 5.5: Antibody-dependent cell-mediated cytotoxicity (ADCC) assay. This example describes an antibody-dependent cell-mediated cytotoxicity (ADCC) assay.

[0092] To evaluate the ADCC function of the antibodies, target cells (CHO cells expressing huCLDN18.2) and effector cells (NK 8837-F cells, ATCC PTA-8837) were used. Target cells were cultured in DMEM-F12 + 10% FBS medium at 2 × 10 cells per well of a 96-well plate in 50 μl for each sample. 4 NK cells were plated at 2 × 10 cells / 50 μl. 100 μl of each antibody serially diluted 1:10 was then added to the cells. After 20 minutes, NK cells were plated at 2 × 10 cells / 50 μl. 5 The cells were added to the plate at a target:effector ratio of 1:10. After this addition, the final concentrations of each antibody were 50 μg / ml, followed by 5, 0.5, and 0.05 μg / ml. The plate was placed in a 37°C CO2 incubator for 24 hours. The cells were then stained with 7AAD, washed twice, and resuspended in approximately 200 μl of FACS buffer. The cells were analyzed by flow cytometry.

[0093] Using unstained cells as a reference, gating across target cells and establishing the 7AAD-negative population allowed us to distinguish between 7AAD (dead cells) and live cells.

[0094] Alternatively, CT26 cells expressing huCLDN18.2 may be used as target cells and ADCC may be determined by LDH.

[0095] A comparison of the ADCC activity of YL-G1-02 and YL-G2-B (which have the same amino acid sequence except for the VLPLL substitution in the Fc region) is shown in Figure 10. EC50 values ​​are summarized in Table 2.

[0096] [Table 2]

[0097] Example 6: Functional characterization of antibodies 6.1: Cell DMEM medium containing 10% FBS (ExCell Bio, Cat. No. FND500) CT26 CLDN18.2 cells (mouse colon cancer cells, Kyinno Biotechnology, Cat. No. KC-1195) maintained in RPMI1640 medium (Gibco, Cat. No. 31053-036) and KATOIII CLDN18.2 cells (human gastric cancer cells, Gibco, Cat. No. 145) maintained in RPMI1640 medium containing 10% FBS. Kyinno Biotechnology, Cat. No. KC-1453), and RPMI 1640 medium containing 10% FBS (Gibco, Cat. No. 22400-089 NCI-N87 CLDN18.2 cells (human gastric cancer cells, Kyinno Biotechnology, Cat. No. KC-1222) maintained in 10% CO₂ medium were used to determine the CDC and ADCC activities of the target antibodies.

[0098] 6.2:CDC assay The CDC activity of the target antibody was measured by measuring the change in LDH levels released into the culture medium after cell lysis. The effect of CT26 CLDN18.2 cells or KATOIII CL DN18.2 cells were suspended in phenol red-free RPMI1640 medium (Gibco, Cat. No. 11835-030) containing 1% FBS at a density of 4E+05 cells / ml, 6E+05 cells / ml, or 1E+06 cells / ml, respectively. RPMI1640 medium without phenol red at 200, 50, 12.5, 3.13, and 0. The antibodies were diluted to 78, 0.195, 0.0488, 0.0122, 0.00305, 0.000763, and 0.000191 nM. Normal human serum complement (Quidel, Cat. No. A113) was diluted 1:50 in phenol red-free RPMI 1640 medium containing 1% FBS. 50 μL of antibody dilution, 50 μL of normal human serum complement dilution, and 50 μL of tumor cell suspension were added to each well of a round-bottom 96-well microplate (Corning, Cat. No. 3799). A human IgG1 isotype antibody was added as a negative control. A reference antibody (IMAB362, Ganymed) was added as a positive control. The microplate was incubated for 3–4 hours in an incubator set at 37°C and 5% CO2. After incubation, LDH release into the cell culture supernatant was detected according to the instructions provided with the LDH Cytotoxicity Assay Kit (Roche, Cat. No. 11644793001). Briefly, the microplate was centrifuged at 1500 rpm for 5 minutes (Eppendorf, model 5810R), and 70 μL of the solution was removed from each well. The supernatant was removed and transferred to a new well on a microplate. Next, 50 μL of LDH detection substrate was added to each well, and the microplate was incubated at room temperature for 0.5–2 hours. SpectraMax M5e (Molecular Devices LLC) was used. The optical density (OD) at 492 nm was detected and the optical density at 690 nm was subtracted (OD492 nm - OD690 nm). The CDC activity of the antibody of interest was calculated using the following formula: The percentage of cytolysis was calculated as: Specific cell lysis (%) = (OD 抗体+補体+腫瘍細胞 -OD 補体+腫瘍細胞 ) * 100 / (OD 腫瘍細胞+Triton -OD 腫瘍細胞 ).

[0099] Data were analyzed by four-parameter nonlinear regression using GraphPad Prism 7 software to obtain EC 50 The value was calculated.

[0100] 6.3: ADCC assay The ADCC activity of the target antibodies was evaluated by measuring the change in the amount of LDH released into the culture medium after cell lysis. NCI-N87 CLDN18.2 cells or KATOIII CLDN18.2 cells were suspended in phenol red-free RPMI 1640 medium at a density of 6E+05 cells / mL. The target antibodies were incubated in phenol red-free RPMI 1640 medium containing 1% FBS. Fresh human PBMC cells (from Saily, volunteer #XC11057W) were diluted in I1640 medium to 20, 4, 0.8, 0.16, 0.032, 0.0064, 1.28E-03, 2.56E-04, 5.12E-05, 1.02E-05, 2.05E-06, 4.10E-07, 8.19E-08, 1.64E-08, 3.28E-09, 6.55E-10, 1.31E-10, 2.62E-11, and 5.24E-12 nM. The cells were suspended in RPMI 1640 medium without any added salt at a density of 1.2E+07 cells / mL. To each well of a 100-well microplate, 50 μL of antibody dilution, 50 μL of human PBMC cell suspension, and 50 μL of tumor cell suspension were added. A human IgG1 isotype antibody was added as a negative control. A reference mAb (IMAB362, Ganymed) was added as a positive control. The microplate was incubated for 4–6 hours in an incubator set at 37°C and 5% CO2. After incubation, LDH release into the cell culture supernatant was detected according to the instructions provided with the LDH cytotoxicity assay kit. The ADCC activity of the target antibody was calculated by the percentage of specific cell lysis using the following formula: Specific cell lysis (%) = (OD 抗体+PBMC+腫瘍細胞 -OD PBMC+腫瘍細胞 ) * 100 / (OD 腫瘍細胞+Triton -OD 腫瘍細胞 ).

[0101] Data were analyzed by four-parameter nonlinear regression using GraphPad Prism 7 software to obtain EC50 The value was calculated.

[0102] 6.4: CDC effect on CT26 CLDN18.2 cells by LDH assay As shown in Figure 11 and Table 3, the two batches of YL-G2-B were YL-G1-19-02, YL-G2-B, YL-G1-19-03, YL-G2-C, YL-G1-19-04, and YL-G2-D all showed stronger CDC effects on CT26 CLDN18.2 cells than the positive control (Figure 11).

[0103] [Table 3]

[0104] 6.5: CDC effect on KATOIII CLDN18.2 cells by LDH assay As shown in Figure 12 and Table 4, the two batches of YL-G2-B were YL-G1-19-02, YL-G2-B, YL-G1-19-03, YL-G2-C, YL-G1-19-04, and YL-G2-D all showed similar CDC effects on KATOIII CLDN18.2 cells (Figure 12, panel A). The CDC effect was stronger than that of the control and positive control (Figure 12).

[0105] [Table 4]

[0106] 6.6: ADCC effect on KATOIII CLDN18.2 cells by LDH assay As shown in Figure 13 and Table 5, the two batches of YL-G2-B were They showed comparable ADCC effects on LDN18.2 cells (Figure 13, panel A). YL-G2-B (EC50 = 0.028 nM or 0.018 nM for different batches), YL-G2-C (EC50 = 0.019 nM), and YL-G2-D (EC50 = 0.021 nM) showed stronger ADCC effects (low EC 50 ) and YL-G1-19-02 (EC 50 = 0.1 6nM), YL-G1-19-03(EC 50 = 0.21nM), YL-G1-19-04( The ADCC effect of the positive control (EC50 = 0.12 nM, 0.22 nM, or 0.27 nM in three runs) on KATOIII CLDN18.2 cells was comparable to that of the positive control (EC50 = 0.12 nM, 0.22 nM, or 0.27 nM in three runs) (Figure 13).

[0107] [Table 5]

[0108] 6.7: ADCC Efficacy Against NCI-N87 CLDN18.2 Cells by LDH Assay Fruit As shown in Figure 14 and Table 6, the two batches of YL-G2-B exhibited comparable ADCC effects against NCI-N87 CLDN18.2 cells (Figure 14, panel A). YL-G2-B (EC50 = 0.0067 nM or 0.012 nM for different batches), YL-G2-C (EC50 = 0.0078 nM), and YL-G2-D (EC50 = 0.0089 nM) exhibited stronger ADCC effects (lower EC50), while YL-G1-19-02 (EC50 = 0.072 nM), YL-G1-19-03 (EC50 = 0.13 nM), and YL-G1-19-04 (EC50 = 0.13 nM) exhibited stronger ADCC effects (lower EC50). 4 (EC50 = 0.067 nM) showed comparable ADCC effects against KATOIII CLDN18.2 cells compared to the positive control (EC50 = 0.057 nM, 0.082 nM, or 0.10 nM in three runs) (Figure 14).

[0109] [Table 6]

[0110] 6.8:SPR The binding affinity of the antibody of interest was determined according to USP 43 IMMUNOLOGICAL TEST METHODS -- SURFACE PLASMON RESONANCE <1105> and C P, 2020 edition, Part IV, General Rules, 3429 IMMUNOCHEMISTRY, NON-LABELING IMMUNOCHEMICAL METHODS (IV) TO SURFACE PLASMON RESONANCE Therefore, measurements were performed by SPR using a human antibody capture kit, type 2 (Cytiva, Cat. No. 29234600). Briefly, anti-human IgG (Fc) antibody was diluted to 25 μg / mL with immobilization buffer and injected onto a Series S Sensor CM5 chip (Cytiva, Cat. No. BR100530) at a flow rate of 10 μL / min for 6 minutes. The coupling secondary antibody yielded approximately 7,000–14,000 response units (RU). Next, the target antibody was diluted to 5 μg / mL in running buffer and injected at a flow rate of 10 μL / min, yielding approximately 200 RU of the coupling primary antibody. For kinetic measurements, two-fold serial dilutions (0.195–50 nM) of His-tagged human Claudin-18.2 were injected at a flow rate of 30 μL / min, yielding approximately 200 RU of the coupling primary antibody. Association was monitored for 120 seconds and dissociation for 300 seconds using acore 8K (Cytiva). The association rate (ka) and dissociation rate (kd) were calculated by simultaneously fitting the association and dissociation sensorgrams using a simple one-to-one binding model. The equilibrium dissociation constant (KD) was calculated as the ratio kd / ka. The results are shown in Table 7 below.

[0111] [Table 7]

[0112] Table 8-1

[0113] Table 8-2

[0114] Table 8-3

[0115] Table 8-4

[0116] Table 8-5

Claims

1. A monoclonal antibody that specifically binds to CLDN18.2, comprising HVR-H1, HVR-H2 and HVR-H3 contained within VH as set forth in SEQ ID NO: 3, and HVR-L1, HVR-L2 and HVR-L3 contained within VL as set forth in SEQ ID NO:

4. A monoclonal antibody.

2. (1) HVR-H1 as represented by SEQ ID NO: 17, HVR-H2 as represented by SEQ ID NO: 18, HVR-H3 as represented by SEQ ID NO: 19, HVR-L1 as represented by SEQ ID NO: 20, HVR-L2 as represented by SEQ ID NO: 21, and HVR-L3 as represented by SEQ ID NO: 22; (2) HVR-H1 as represented by SEQ ID NO: 41, HVR-H2 as represented by SEQ ID NO: 42, HVR-H3 as represented by SEQ ID NO: 43, HVR-L1 as represented by SEQ ID NO: 44, HVR-L2 as represented by SEQ ID NO: 45, and HVR-L3 as represented by SEQ ID NO: 46; (3) HVR-H1 as represented by SEQ ID NO: 47, HVR-H2 as represented by SEQ ID NO: 48, HVR-H3 as represented by SEQ ID NO: 49, HVR-L1 as represented by SEQ ID NO: 50, HVR-L2 as represented by SEQ ID NO: 51, and HVR-L3 as represented by SEQ ID NO: 52; or (4) The monoclonal antibody of claim 1, comprising HVR-H1 as represented by SEQ ID NO: 53, HVR-H2 as represented by SEQ ID NO: 54, HVR-H3 as represented by SEQ ID NO: 55, HVR-L1 as represented by SEQ ID NO: 56, HVR-L2 as represented by SEQ ID NO: 57, and HVR-L3 as represented by SEQ ID NO:

58.

3. 2. The monoclonal antibody of claim 1, comprising a VH as represented by SEQ ID NO: 3 and a VL as represented by SEQ ID NO:

4.

4. The monoclonal antibody of any one of claims 1 to 3, which is a murine antibody, a chimeric antibody or a humanized antibody.

5. The monoclonal antibody according to any one of claims 1 to 3, which is a full-length antibody.

6. 6. The monoclonal antibody of claim 5, comprising: Human IgG heavy chain constant region, and / or human kappa light chain constant region.

7. The monoclonal antibody described in Claim 6, wherein the heavy chain constant region of human IgG is the heavy chain constant region of IgG1.

8. A monoclonal antibody described in claim 3, comprising a human IgG1 heavy chain constant region represented by sequence number 9 and / or a human kappa light chain constant region represented by sequence number 10.

9. Fab fragment, Fab' fragment, F(ab') ２ The monoclonal antibody of any one of claims 1 to 3, which is an antigen-binding antibody fragment selected from the group consisting of a IgG fragment, an scFv fragment, and a diabody.

10. The monoclonal antibody of any one of claims 1 to 3, wherein the monoclonal antibody is isolated, naked, and / or conjugated.

11. An Fc-engineered monoclonal antibody that specifically binds to CLDN18.2, comprising HVR-H1, HVR-H2 and HVR-H3 contained within VH as set forth in SEQ ID NO: 3, and HVR-L1, HVR-L2 and HVR-L3 contained within VL as set forth in SEQ ID NO: 4, and comprising one or more mutations in the Fc region.

12. (1) HVR-H1 as represented by SEQ ID NO: 17, HVR-H2 as represented by SEQ ID NO: 18, HVR-H3 as represented by SEQ ID NO: 19, HVR-L1 as represented by SEQ ID NO: 20, HVR-L2 as represented by SEQ ID NO: 21, and HVR-L3 as represented by SEQ ID NO: 22; (2) HVR-H1 as represented by SEQ ID NO: 41, HVR-H2 as represented by SEQ ID NO: 42, HVR-H3 as represented by SEQ ID NO: 43, HVR-L1 as represented by SEQ ID NO: 44, HVR-L2 as represented by SEQ ID NO: 45, and HVR-L3 as represented by SEQ ID NO: 46; (3) HVR-H1 as represented by SEQ ID NO: 47, HVR-H2 as represented by SEQ ID NO: 48, HVR-H3 as represented by SEQ ID NO: 49, HVR-L1 as represented by SEQ ID NO: 50, HVR-L2 as represented by SEQ ID NO: 51, and HVR-L3 as represented by SEQ ID NO: 52; or (4) A monoclonal antibody described in claim 11, comprising HVR-H1 as represented by SEQ ID NO: 53, HVR-H2 as represented by SEQ ID NO: 54, HVR-H3 as represented by SEQ ID NO: 55, HVR-L1 as represented by SEQ ID NO: 56, HVR-L2 as represented by SEQ ID NO: 57, and HVR-L3 as represented by SEQ ID NO:

58.

13. 12. The monoclonal antibody of claim 11, comprising a VH as represented by SEQ ID NO: 3 and a VL as represented by SEQ ID NO: 4, and optionally, the first two amino acid residues at the N-terminus of the VH are absent.

14. The monoclonal antibody according to any one of claims 11 to 13, which is a chimeric or humanized antibody.

15. The monoclonal antibody of any one of claims 11 to 13, wherein the one or more mutations in the Fc region are one or more mutations that modify (e.g., increase or decrease) Fc receptor binding and / or effector function, such as ADCC and / or CDC.

16. 16. The monoclonal antibody of claim 15, wherein the one or more mutations in the Fc region are one or more substitutions selected from the group consisting of L235V, F243L, R292P, Y300L and P396L.

17. The monoclonal antibody according to any one of claims 11 to 13, comprising a human IgG heavy chain constant region and / or a human kappa light chain constant region.

18. The monoclonal antibody described in Claim 17, wherein the heavy chain constant region of human IgG is the heavy chain constant region of human IgG1.

19. A monoclonal antibody described in claim 13, comprising a human IgG1 heavy chain constant region represented by sequence number 40 and / or a human kappa light chain constant region represented by sequence number 10.

20. The monoclonal antibody of any one of claims 11 to 13, wherein the monoclonal antibody is isolated, naked, and / or conjugated.

21. An isolated nucleic acid encoding the monoclonal antibody of any one of claims 1 to 3, 8, 11 to 13, and 19.

22. A vector comprising the nucleic acid of claim 21.

23. A host cell comprising the nucleic acid of claim 21.

24. A method for producing a monoclonal antibody, comprising culturing a host cell according to claim 23 so as to produce the antibody, and recovering the antibody from the host cell or cell culture medium, wherein the antibody is encoded by the nucleic acid contained in the host cell.

25. A composition comprising the monoclonal antibody of any one of claims 1 to 3, 8, 11 to 13, and 19.

Images